Panag Pharma Completes Phase 3 Trial With Awaye™

    NEXT STORY
    G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference
    PREV STORY
    ELSAH-PROJEKT SETZT NEUE MASSSTÄBE BEI WEARABLES
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ChemioCare Reports Positive Animal Study Results for CMIO-Ondan Patch

    NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the ...

    author_avatar
    NASDAQ Market News

    Affimed to Host Hodgkin’s Lymphoma Day with Key Opinion Leaders on January 26th in New York City

    HEIDELBERG, Germany, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage ...

    author_avatar
    NASDAQ Market News

    UPDATE — ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

    ― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to ...

    author_avatar
    NASDAQ Market News